Compare Dow Jones Industrial Average ETF (DIA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Viatris Inc — how do they compare? Dow Jones Industrial Average ETF trades at $513.2 (market cap $45.20B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: Dow Jones Industrial Average ETF is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Viatris Inc for 57 Days on average.
| DIA | VTRS | |
|---|---|---|
Market Cap | $45.20B | $20.03B |
Volume | 4,095,368 | 14,109,977 |
52-Week High | $542.79 | $18.27 |
52-Week Low | $451.37 | $9.74 |
Typical Hold Time | 103 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $513.34, showing modest 0.45% daily gains amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent dividend distributions provide income appeal, but key valuation metrics are unavailable for comprehensive fundamental assessment. Market sentiment reflects broader equity concerns as highlighted in recent financial coverage.
The outlook remains cautious given technical weakness and market volatility. Dividend payments offer income stability, but the absence of fundamental metrics limits valuation clarity. Key risks include broader market pressures and economic uncertainty, requiring careful monitoring of Dow Jones component performance for directional cues.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
